Eidos Therapeutics, Inc.

With $145m in new capital, Apollo Therapeutics LLC is looking to move to the next level by taking its 15-plus preclinical programs sourced from three UK universities into clinical development. As Ap

BridgeBio Pharma, Inc. appears off to a solid start with its program to develop encaleret for patients with autosomal dominant hypocalcemia type 1 (ADH1), releasing proof-of-concept data showing stro

Since its inception in 2015, BridgeBio Pharma, Inc. has employed a hub-and-spoke business model similar to those used by Roivant Sciences Ltd. and Fortress Biotech Inc. , putting its expertise an

The Dutch firm argenx N.V. closed a follow-on public offering (FOPO) in the US and concurrent private placement of ordinary shares in Europe on 4 February that grossed $1.15bn to fund the company’s